CD4+ T细胞免疫重建预测急性移植物抗宿主病后的生存结局:双中心验证
该回顾性双中心研究纳入591例首次接受异基因造血干细胞移植的儿童患者,分析CD4+ T细胞免疫重建(CD4+ IR,定义为移植后100天内或aGVHD发生前CD4+ T细胞≥50个/μL)与aGVHD后生存的关系。结果显示,在3-4级aGVHD患者中,未实现CD4+ IR与显著更高的非复发死亡率和更差的总生存相关。
要点
- CD4+ IR定义为移植后100天内或aGVHD发生前CD4+ T细胞≥50个/μL。
- 3-4级aGVHD且无CD4+ IR者非复发死亡率显著高于有CD4+ IR者。
- aGVHD发生前CD4+ IR不足与更高的NRM和更差OS显著相关。
核心结论
- 早期CD4+ IR是预测HCT后结局的简单稳健标志物,与中重度aGVHD后的生存相关。
研究设计与样本
- 回顾性双中心分析,纳入在UMC/PMC或MSK接受首次异基因HCT的儿童患者共591例(UMC/PMC n=276;MSK n=315)。
- 采用多因素和时间事件Cox比例风险模型分析。
主要发现
- 3-4级aGVHD患者中,移植后100天内有无CD4+ IR的NRM:UMC/PMC为30% vs 80%(P=.02),MSK为5% vs 67%(P=.02)。
- 无CD4+ IR与更低OS相关:UMC/PMC为61% vs 20%(P=.04);MSK为75% vs 33%(P=.12)。
- aGVHD发生前CD4+ IR不足与显著更高的NRM(74% vs 12%;P<.001)和更差OS(24% vs 78%;P<.001)相关。
关键数值与推荐
- CD4+ IR定义为移植后100天内或aGVHD发生前CD4+ T细胞≥50个/μL。
临床怎么用
- 早期CD4+ IR可用于识别中重度aGVHD后高死亡风险患者,提示改善T细胞恢复的策略可能影响生存。
局限性
- 该关联需前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+ T-cell immune reconstitution (IR; CD4+ IR) predicts survival after HCT. Here, we studied the relation between CD4+ IR and survival in patients developing aGVHD. Pediatric patients undergoing first allogeneic HCT at University Medical Center Utrecht (UMC)/Princess Máxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were included. Primary outcomes were nonrelapse mortality (NRM) and overall survival (OS), stratified for aGVHD and CD4+ IR, defined as ≥50 CD4+ T cells per μL within 100 days after HCT or before aGVHD onset. Multivariate and time-to-event Cox proportional hazards models were applied, and 591 patients (UMC/PMC, n = 276; MSK, n = 315) were included. NRM in patients with grade 3 to 4 aGVHD with or without CD4+ IR within 100 days after HCT was 30% vs 80% (P = .02) at UMC/PMC and 5% vs 67% (P = .02) at MSK. This was associated with lower OS without CD4+ IR (UMC/PMC, 61% vs 20%; P = .04; MSK, 75% vs 33%; P = .12). Inadequate CD4+ IR before aGVHD onset was associated with significantly higher NRM (74% vs 12%; P < .001) and inferior OS (24% vs 78%; P < .001). In this retrospective analysis, we demonstrate that early CD4+ IR, a simple and robust marker predictive of outcomes after HCT, is associated with survival after moderate to severe aGVHD. This association must be confirmed prospectively but suggests strategies to improve T-cell recovery after HCT may influence survival in patients developing aGVHD.
引用
- de Koning C, Prockop S, van Roessel I, et al. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood. 2021. PMID: 33150379. doi:10.1182/blood.2020007905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。